NMDAR2A Antibody - C-terminus - Azide Free

Western Blot: NMDAR2A Antibody [NB300-105] - GluN2B to GluN2A NMDAR switch and Ppt1-/--induced synaptic deficits are recapitulated in primary cortical neurons. (B) Representative immunoblot (top) and quantification of GluN2A levels (bottom) in WT and Ppt1-/- neurons at DIV7, 10, and 18. (D) Representative immunoblot (top) and quantification of the GluN2A/2B ratio (bottom) in WT and Ppt1-/- neurons at DIV7, 10, and 18. For all experiments in Figure 5, Ppt1-/- and WT were compared (n = 2 independent experiments with two repetitions/group) at each time point using t-test and the significance indicated as follows: *p<0.05 where indicated. Error bars represent s.e.m. Image collected and cropped by CiteAb from the following publication (//elifesciences.org/articles/40316) licensed under a CC-BY license.

Western Blot: NMDAR2A Antibody [NB300-105] - Hyperpalmitoylation of Fyn kinase and GluN2B is reversed in Ppt1-/- primary cortical neurons by palmitoylation inhibitor treatment. Representative post-APEGS immunoblot of GluN2A (NMDAR2A) with beta-actin loading control. Image collected and cropped by CiteAb from the following publication (//elifesciences.org/articles/40316), licensed under a CC-BY license.

Immunohistochemistry: NMDAR2A Antibody [NB300-105] - Immunostaining of rabbit retina showing NR2A in the rod and cone photoreceptors in the outer plexiform layer as well as the entire inner plexiform layer.

Western Blot: NMDAR2A Antibody [NB300-105]

Western Blot: NMDAR2A Antibody [NB300-105] - NMDAR subunit composition is immature in whole lysates from Ppt1-/- visual cortex.(A) Representative immunoblots of the GluN2A in whole lysates across age & genotype as indicated (top) & quantification of band density (bottom) normalized to beta -actin loading control within lane. (B) Representative immunoblots of the GluN2B in whole lysates across age & genotype as indicated (top) & quantification of band density (bottom) normalized to beta -actin loading control within lane. (C) Representative immunoblots of GluN2A & GluN2B (top) from whole lysates across age & genotype & quantification of the ratio of GluN2A/GluN2B band density within animal (bottom). (D) Representative immunoblots of GluN1 in whole lysates across age & genotype as indicated (top) & quantification of band density (bottom) normalized to beta -actin loading control within lane. (E) Representative immunoblot from whole lysates of PPT1 across age & genotype as indicated (top) & protein expression level (bottom) normalized to beta -actin. For experiments in Figure 2—figure supplement 1A–C, Ppt1-/- & WT were compared (n = 4 independent experiments/animals with two repetitions/group) at each age using t-test & the significance is indicated: *p<0.05. In Figure 2D, WT expression levels at each age were compared (n = 4 independent experiments/animals with two repetitions/group) by ANOVA followed by Tukey’s post-hoc test. Significance between ages is indicated: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Error bars represent s.e.m. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30946007), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: NMDAR2A Antibody [NB300-105] - GluN2B to GluN2A NMDAR switch & Ppt1-/--induced synaptic deficits are recapitulated in primary cortical neurons.(A) Representative immunoblot (top) & quantification of GluN2B levels in WT & Ppt1-/- neurons at DIV7, 10, & 18. (B) Representative immunoblot (top) & quantification of GluN2A levels (bottom) in WT & Ppt1-/- neurons at DIV7, 10, & 18. (C) Representative immunoblot (top) & quantification of PSD-95 levels (bottom) in WT & Ppt1-/- neurons at DIV7, 10, & 18. (D) Representative immunoblot (top) & quantification of the GluN2A/2B ratio (bottom) in WT & Ppt1-/- neurons at DIV7, 10, & 18. For all experiments in Figure 5, Ppt1-/- & WT were compared (n = 2 independent experiments with two repetitions/group) at each time point using t-test & the significance indicated as follows: *p<0.05 where indicated. Error bars represent s.e.m. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30946007), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: NMDAR2A Antibody [NB300-105] - NMDAR subunit composition is immature in whole lysates from Ppt1-/- visual cortex.(A) Representative immunoblots of the GluN2A in whole lysates across age & genotype as indicated (top) & quantification of band density (bottom) normalized to beta -actin loading control within lane. (B) Representative immunoblots of the GluN2B in whole lysates across age & genotype as indicated (top) & quantification of band density (bottom) normalized to beta -actin loading control within lane. (C) Representative immunoblots of GluN2A & GluN2B (top) from whole lysates across age & genotype & quantification of the ratio of GluN2A/GluN2B band density within animal (bottom). (D) Representative immunoblots of GluN1 in whole lysates across age & genotype as indicated (top) & quantification of band density (bottom) normalized to beta -actin loading control within lane. (E) Representative immunoblot from whole lysates of PPT1 across age & genotype as indicated (top) & protein expression level (bottom) normalized to beta -actin. For experiments in Figure 2—figure supplement 1A–C, Ppt1-/- & WT were compared (n = 4 independent experiments/animals with two repetitions/group) at each age using t-test & the significance is indicated: *p<0.05. In Figure 2D, WT expression levels at each age were compared (n = 4 independent experiments/animals with two repetitions/group) by ANOVA followed by Tukey’s post-hoc test. Significance between ages is indicated: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Error bars represent s.e.m. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30946007), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: NMDAR2A Antibody [NB300-105] - GluN2B to GluN2A NMDAR switch & Ppt1-/--induced synaptic deficits are recapitulated in primary cortical neurons.(A) Representative immunoblot (top) & quantification of GluN2B levels in WT & Ppt1-/- neurons at DIV7, 10, & 18. (B) Representative immunoblot (top) & quantification of GluN2A levels (bottom) in WT & Ppt1-/- neurons at DIV7, 10, & 18. (C) Representative immunoblot (top) & quantification of PSD-95 levels (bottom) in WT & Ppt1-/- neurons at DIV7, 10, & 18. (D) Representative immunoblot (top) & quantification of the GluN2A/2B ratio (bottom) in WT & Ppt1-/- neurons at DIV7, 10, & 18. For all experiments in Figure 5, Ppt1-/- & WT were compared (n = 2 independent experiments with two repetitions/group) at each time point using t-test & the significance indicated as follows: *p<0.05 where indicated. Error bars represent s.e.m. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30946007), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

• Reactivity: Hu, Mu, Rt, Rb
• Applications: WB, IHC, IP, KO
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: Azide Free

NMDAR2A Antibody - C-terminus - Azide Free Summary

• Description: PLEASE NOTE: If 0.01mg size is ordered, product will come lyophilized from 5 mM ammonium bicarbonate. Please reconstitute lyophilized product in 50 ul phosphate buffered saline (PBS: 137 mM NaCl, 7.5 mM Na2HPO4, 2.7 mM KCl, 1.5 mM KH2PO4, pH 7.4)
• Immunogen: Fusion protein from the C-terminal region of the NR2A subunit. Accession # Q00959
• Localization: NB 300-105 can be used to demonstrate that both the NR2A is highly enriched in hippocampus compared to either cortex or cerebellum.
• Specificity: Specific for endogenous levels of the ~180 kDa NR2A subunit of the NMDA receptor. No reactivity towards the NR2B and NR2C subunits. Immunolabeling is blocked by pre-adsorption of antibody with the fusion protein used to generate the antibody.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: GRIN2A
• Purity: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 1:1000 - 1:2000
  • Immunohistochemistry-Paraffin 1:1000
  • Immunoprecipitation 3 ul per 200 ug lysate
  • Knockout Validated
  • Western Blot 1:1000
• Application Notes: NB 300-105 can be used in Western blot where a band is seen at ~ 180 kDa representing the NMDAR2A.
• Theoretical MW: 180 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Reactivity Notes

Use in Mouse reported in scientific literature (PMID:35354047).

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: 10mM HEPES (pH 7.5), 0.15M NaCl, 0.1 mg/ml BSA and 50% Glycerol
• Preservative: No Preservative
• Purity: Antigen Affinity-purified

Alternate Names for NMDAR2A Antibody - C-terminus - Azide Free

• GluN2A
• glutamate receptor, ionotropic, N-methyl D-aspartate 2A
• hNR2A
• NMDA receptor subtype 2A
• N-methyl D-aspartate receptor subtype 2A
• N-methyl-D-aspartate receptor subunit 2A
• subunit epsilon-1

Background

The ion channels activated by glutamate are divided into two classes. Those that are sensitive to N-methyl-D-aspartate (NMDA) are designated NMDA receptors (NMDAR) while those activated by kainate and a-amino-3-hydroxy-5-methyl-4-isoxalone propionic acid (AMPA) are known as kainate/AMPA receptors (K/AMPAR). NMDA receptors are among the most studied receptors in neuroscience because they are involved in neuronal cell development and plasticity, a cellular correlate for learning. NMDA receptors are also implicated in several disorders of the central nervous system including epilepsy and ischemic neuronal cell death. NMDA receptors also appear to be a target for ethanol at physiological concentrations and therefore may play a significant role in alcoholism.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for NMDAR2A Antibody (NB300-105)(15)

Publications using NB300-105

• Funke JR, Hwang EK, Wunsch AM et al. Persistent neuroadaptations in the nucleus accumbens core accompany incubation of methamphetamine craving in male and female rats eNeuro 2023-02-13 [PMID: 36792361] (WB, Rat)
• Zhou J, Geng Y, Su T et al. NMDA receptor-dependent prostaglandin-endoperoxide synthase 2 induction in neurons promotes glial proliferation during brain development and injury Cell reports 2022-03-29 [PMID: 35354047] (WB, Mouse)
• Yu XJ, Xiao T, Liu XJ et al. Effects of Nrf1 in Hypothalamic Paraventricular Nucleus on Regulating the Blood Pressure During Hypertension Frontiers in neuroscience 2021-12-06 [PMID: 34938159] (WB, Rat)
• Ni J, Ren Y, Su T Et al. Loss of TDP-43 function underlies hippocampal and cortical synaptic deficits in TDP-43 proteinopathies Molecular psychiatry 2021-10-25 [PMID: 34697451]
• Jiang A, Su P, Li S et al. Disrupting the alpha 7nAChR-NR2A protein complex exerts antidepressant-like effects Molecular brain 2021-07-05 [PMID: 34225758] (WB)
• Li Y, Lu YX, Chi HL et al. Chronic Blockade of NMDAR Subunit 2A in the Hypothalamic Paraventricular Nucleus Alleviates Hypertension through Suppression of MEK/ERK/CREB Pathway American journal of hypertension 2021-04-15 [PMID: 33856436]
• Hassani Nia, F, Woike, D Et al. Targeting of delta-catenin to postsynaptic sites through interaction with the Shank3 N-terminus. Mol Autism 2020-10-28 [PMID: 33115499] (ICC/IF, Human)
• Koster K, Francesconi W, Berton F et al. NMDA Receptor Dysregulation by Defective Depalmitoylation in the Infantile Neuronal Ceroid Lipofuscinosis Mouse Model bioRxiv 2018-08-13 [PMID: 30946007] (WB, Mouse)
• Koster, KP;Francesconi, W;Berton, F;Alahmadi, S;Srinivas, R;Yoshii, A; Developmental NMDA receptor dysregulation in the infantile neuronal ceroid lipofuscinosis mouse model Elife 2019-04-04 [PMID: 30946007] (WB, Mouse)
• Wang X, Zhao L, Zhang J et al. Requirement for Microglia for the Maintenance of Synaptic Function and Integrity in the Mature Retina. J Neurosci 2016-03-02 [PMID: 26937019] (IF/IHC)
• Lo SC, Wang Y, Weber M et al. Caspase-3 deficiency results in disrupted synaptic homeostasis and impaired attention control J. Neurosci. 2015-02-04 [PMID: 25653368] (WB, Mouse)
  
  Details:
  NMDAR2A (GluN2A/NR2A) antibody used for WB analysis of the lysates from hippocampus tissues which were collected from experienced mice (11 months of age; tissues collected 1 month after the last behavior testing ) from WT and Casp3?/? mice genotypes previously subjected to repeated challenges with new behavioral testing (Figure 7B).
• Hanson JE, Pare J, Deng L et al. Altered GluN2B NMDA receptor function and synaptic plasticity during early pathology in the PS2APP mouse model of Alzheimer's disease. Neurobiol. Dis. 2014-12-04 [PMID: 25484285] (WB, Mouse)
  
  Details:
  NMDAR2A antibody used for WB at 1:1000 dilution on brain lysates from male mice homozygous for the PS2APP transgenes (mouse model of Alzheimer's disease) and their wt littermate controls.
• Das SR, Magnusson KR. Changes in expression of splice cassettes of NMDA receptor GluN1 subunits within the frontal lobe and memory in mice during aging. Behav Brain Res;222(1):122-133. 2011-09-12 [PMID: 21443909] (WB, Mouse)
• Karolewicz B, Szebeni K, Gilmore T et al. Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression. Int J Neuropsychopharmacol 2009-03-01 [PMID: 18570704] (WB, Human)
• Ning, K et al. Dual Neuroprotective Signaling Mediated by Downregulating Two Distinct Phosphatase Activities of PTEN. The Journal of Neuroscience; 24: 4052-4060. 2004-01-01 [PMID: 15102920] (WB, IP, Rat)

Bioinformatics

• Gene Symbol: GRIN2A
• Entrez:
  • 2903(Human)
  • 24409(Rat)
• Uniprot:
  • Q00959(Rat)